High Content Screening Market Poised for Growth, Projected to Reach USD 2.7 Billion by 2032 at a 5.8% of CAGR

The high content screening market is on track for substantial growth, with the overall valuation expected to increase from USD 1.6 billion in 2022 to approximately USD 2.7 billion by 2032. This growth trajectory, supported by a projected compound annual growth rate (CAGR) of 5.8%, highlights the increasing adoption of advanced screening technologies across various sectors.

High content screening (HCS) is a powerful analytical method used in drug discovery and cell biology to conduct automated microscopy and quantitative analysis of cellular events. The growth in the HCS market is driven by the rising need for sophisticated screening techniques in drug discovery, the increasing prevalence of chronic diseases, and advancements in imaging technologies.

Get Your Insightful Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-426

Finding and developing new drugs involves the use of high content screening. The increasing amount of research being done on target identification and validation, along with the ongoing quest for new drug candidates, is predicted to drive an acceleration in the adoption of high content screening over the next few years. Furthermore, it is projected that demand will rise over the course of the projection period as a result of a continued emphasis on manufacturing high-quality and technologically advanced cell imaging systems.

Nevertheless, the COVID-19 pandemic significantly impeded investigations and advancements. The market is anticipated to suffer as a result of this. However, it is anticipated that the market will grow in the upcoming years due to a rise in the amount of money major manufacturers are investing in the creation of cutting-edge cell imaging products.

Key Takeaways

• The CAGR for the global market over the preceding period was 5.1%.
• Over the coming decades, the market in India is anticipated to grow at a CAGR of 6.6%.
• With more than 7.3% of all demand recorded in Europe in 2022, Germany has emerged as a major market.
• Over the coming decade, the market in China is anticipated to grow at a CAGR of 7.8%.
• The highest demand for High Content Screenings came from the pharmaceutical and healthcare industries.

“The rising prevalence of multiple infectious diseases with a variety of symptoms raises the demand for innovative treatments. As a result, there will be an increase in biotechnology and pharmaceutical study and development efforts to identify new drug candidates. Imaging technologies are becoming increasingly important in drug discovery and analysis.” says an FMI analyst.

Competitive Landscape:

Key players in the HCS market employ strategies such as mergers and acquisitions, product launches, collaborations, and alliances to expand their businesses.

• Particle Works, a progressive company that creates and markets cutting-edge particle engineering platforms, declared the release of the Automated Library Synthesis (ALiS) System, a new ground-breaking platform, in November 2022. This innovative platform favors automation in the early stages of the creation of drugs as well as high-throughput evaluation of lipid nanoparticle (LNP) formulations and mRNA candidates.
• The Twist High Throughput Antibody Production platform, developed by California-based Twist Bioscience Corporation, was made public in April 2022. It allows customers to convert candidate genetic sequences into cleansed antibodies for use in a variety of applications related to screening and therapeutic discovery projects.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-426

Key Companies Profiled: 

• Thermo Fisher Scientific Inc.
• Becton Dickinson, and Company
• GE Healthcare
• Olympus Corporation
• PerkinElmer Inc.
• Sysmex Corporation
• Merck KGaA
• Danaher Corporation
• Yokogawa Electric Corporation
• BioTek Instruments Inc.

Key Segments Profiled in the High Content Screening Industry Survey:

Product Type:

• Cell Imaging & Analysis
  • HCS Instruments
    • High-End HCS
    • Mid End HCS
    • Low-End HCS
  • Flow Cytometers
• Consumables
  • Microplates
  • Reagents & Assay Kits
  • Other Consumables
• Software
• Services

Industry:

• Pharmaceutical & Healthcare
• Biotechnology
• Educational Institutions
• Independent CRO
• Government Organizations
• Others

Application:

• Primary & Secondary Screening
• Target Identification & Validation
• Toxicity Studies
• Compound Profiling
• Others

Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa

Get Full Market Analysis Now: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/426

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube